Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 693 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 693 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.19, for a total transaction of $22,307.67. Following the transaction, the insider directly owned 175,868 shares in the company, valued at approximately $5,661,190.92. The trade was a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jason Adair also recently made the following trade(s):

• On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The shares were sold at an average price of $30.03, for a total transaction of $1,070,749.68.
• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The stock was sold at an average price of $22.93, for a total transaction of $15,867.56.
• On Monday, October 13th, Jason Adair sold 3,670 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total transaction of $85,914.70.

Liquidia Stock Down 3.9%

Shares of Liquidia stock opened at $30.79 on Wednesday. Liquidia Corporation has a 1-year low of $10.37 and a 1-year high of $32.80. The company has a market capitalization of $2.68 billion, a PE ratio of -21.38 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The business has a 50-day moving average of $25.57 and a 200-day moving average of $21.56.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The business’s quarterly revenue was up 1106.7% compared to the same quarter last year. As a group, equities analysts forecast that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on LQDA. Raymond James Financial reiterated a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research note on Tuesday, November 4th. Needham & Company LLC upped their target price on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price target on shares of Liquidia in a research note on Monday, November 3rd. Finally, BTIG Research restated a “buy” rating and set a $49.00 price objective on shares of Liquidia in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.56.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently made changes to their positions in LQDA. Caxton Associates LLP acquired a new stake in shares of Liquidia during the 3rd quarter worth approximately $389,000. TCG Crossover Management LLC acquired a new position in Liquidia during the 3rd quarter valued at approximately $38,887,000. Voloridge Investment Management LLC bought a new position in Liquidia during the 3rd quarter worth $12,571,000. Scientech Research LLC acquired a new stake in Liquidia in the third quarter worth $237,000. Finally, Qube Research & Technologies Ltd bought a new stake in Liquidia in the third quarter valued at $2,137,000. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).